Introduction {#section1-1076029618774146}
============

Abdominal vein thrombosis includes portal vein thrombosis (PVT) and mesenteric vein thrombosis (MVT). Portal vein thrombosis is venous thrombosis occurring in the trunk of the portal vein including portal branches such as the mesenteric and splenic veins.^[@bibr1-1076029618774146],[@bibr2-1076029618774146]^ Mesenteric vein thrombosis commonly involves the superior mesenteric vein, known as superior mesenteric vein thrombosis (SMVT), and rarely the inferior mesenteric vein. In SMVT,^[@bibr3-1076029618774146]^ local blood coagulation impairs the venous return of the bowel and causes ischemic changes and necrosis of the bowel wall. As SMVT is a relatively rare condition with nonspecific symptoms and insufficient clinician awareness, the mortality rate remains high due to a delayed diagnosis. The frequency of nonneoplastic PVT in patients with liver cirrhosis is about 7.2% to 17%^[@bibr4-1076029618774146],[@bibr5-1076029618774146]^ and is higher at the decompensated or advanced stage.^[@bibr5-1076029618774146],[@bibr6-1076029618774146]^ Although acute PVT can be severe and may lead to mesenteric ischemia and variceal bleeding, there are many cases of nonsymptomatic PVT.^[@bibr7-1076029618774146]^ The frequency of SMVT ranged from 1 of 5000 to 1 of 15 000 among inpatients and 1 of 1000 among emergency department admissions, accounting for 6% to 9% of all cases of acute mesenteric ischemia.^[@bibr8-1076029618774146]^ Portal vein thrombosis is also a frequent complication of splenectomy^[@bibr7-1076029618774146]^ and liver transplantation.^[@bibr9-1076029618774146]^ Primary SMVT develops spontaneously and is idiopathic, and secondary SMVT arises from underlying diseases or risk factors. A delayed diagnosis or treatment of SMVT allows intestinal infarction to develop, which can be life-threatening. Thrombophilia,^[@bibr10-1076029618774146]^ such as plasminogen activator inhibitor I 4G-4G, methylene tetrahydrofolate reductase (MTHFR) 677TT, factor V Leiden 506Q, prothrombin 20210A, and antithrombin (AT), protein C (PC), and protein S (PS) abnormalities, can frequently cause PVT or MVT. Few reports have explored the prevalence of MTHFR 677TT, factor V Leiden 506Q, and prothrombin 20210A in Japan.

In this study, the differences between PVT and SMVT, including abnormalities in AT, PC, and PS, were examined in 21 patients with PVT, 6 patients with SMVT, and 6 patients with both PVT and SMVT in order to confirm the relationship between thrombophilia and SMVT.

Materials and Methods {#section2-1076029618774146}
=====================

The study protocol was approved by the Human Ethics Review Committee of the Mie University School of Medicine, and a signed consent form was obtained from each patient. This study was faithfully carried out in accordance with the Declaration of Helsinki. Deep vein thrombosis (DVT) was diagnosed using echography or venography, and disseminated intravascular coagulation (DIC) was diagnosed according to the International Society of Thrombosis and Haemostasis overt DIC diagnostic criteria.^[@bibr10-1076029618774146]^ Cerebral vascular disease was diagnosed with computed tomography or magnetic resonance imaging (MRI), and cerebral venous sinus thrombosis (CVST) was diagnosed based on MRI, magnetic resonance venography, or cerebral angiography (CAG) findings.^[@bibr11-1076029618774146],[@bibr12-1076029618774146]^

Measurement of the AT, PC, PS, and Antiphospholipid Antibody Concentrations {#section3-1076029618774146}
---------------------------------------------------------------------------

Peripheral blood samples were collected in a 1/10 volume of 3.13% sodium citrate. The free PS antigen concentration was measured using a monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) with the Asserachrom free PS kit (Diagnostica Stago, Asnières, France). The plasma PS and PC activity levels were measured according to the clotting time method using STA-Staclot PS and STA-Staclot PC kit (Diagnostica Stago). The plasma PC antigen concentration was measured based on a latex agglutination test using a LPIA-ACE PC kit (Mitsubishi Chemical Medience Corporation, Tokyo, Japan). The plasma AT activity was measured according to a synthetic substrate assay using a Chromorate ATIII (C) kit (Mitsubishi Chemical Medience Corporation). The dilute Russell's viper venom time was measured with the clotting time method using a Gradipore LA test (Gradipore, Sydney, Australia). The titers of anti-cardiolipin-β2-glycoprotein I antibodies were measured with an ELISA kit (Yamasa Co, Tokyo, Japan).^[@bibr13-1076029618774146]^

Gene Analyses of AT, PC, and PS {#section4-1076029618774146}
-------------------------------

Genomic DNA was prepared from peripheral blood leukocytes using a QIAamp DNA blood mini kit (QIAGEN, Venlo, Netherlands) according to the manufacturer's instructions. Each exon and exon/intron boundary of the gene was amplified from genomic DNA using polymerase chain reaction (PCR), as previously described. The PCR products were directly sequenced using a Big-Dye terminator cycle sequencing kit and Applied Biosystems 3130 genetic analyzer (Applied Biosystems, Foster City, California).^[@bibr14-1076029618774146]^ Gene analyses were carried out in cases with AT, PC, or PS levels less than 70% without warfarin treatment or liver failure.

Statistical Analyses {#section5-1076029618774146}
--------------------

The data are expressed as the median (25th percentile to 75th percentile). Differences between the groups were examined for statistical significance using the Mann-Whitney *U* test. A *P* value \<.05 denoted the presence of a statistically significant difference.

Results {#section6-1076029618774146}
=======

In all, 12 patients with SMVT (median age, 49.5 years; 2th percentile to 75th percentile, 40.0-67.0 years; 3 females and 9 males) and 27 patients with PVT (median, 61.5 years; 25th percentile to 75th percentile, 55.0-77.0 years; 11 females and 16 males) were examined at Mie University Hospital between January 4, 1992, and December 28, 2016 ([Tables 1](#table1-1076029618774146){ref-type="table"} and [2](#table2-1076029618774146){ref-type="table"}). Both SMVT and PVT were diagnosed by echography or computed tomography. Ten patients with PVT and 1 patient with SMVT were diagnosed after surgery, and SMVT was unexpectedly diagnosed in most patients. Twelve patients with SMVT were associated with 6 PVT, 4VST, 1VT, and 1 cerebral thrombosis, and 4 patients had relapse. Of 27 patients with PVT, 6 were associated with SMVT, 4 DIC, 3 DVT, 3 CVST, 1 cerebral thrombosis, 1 major bleeding, and 1 pulmonary embolism (PE). Six patients were associated with both MVT and PVT. There were no significant differences in the age or sex between patients with SMVT and PVT ([Tables 1](#table1-1076029618774146){ref-type="table"} and [2](#table2-1076029618774146){ref-type="table"}). The cause of the onset of PVT was postoperative complication in 10 patients, idiopathic in 5 patients, pancreatic cancer in 4 patients, biliary duct cancer in 3 patients, living donor liver transplantation in 2 patients, liver failure in 2 patients, other cancers in 4 patients, and other causes in 4 patients. The cause of SMVT onset was idiopathic in 8 patients, biliary duct cancer in 2 patients, APS in 1 patient, and postoperative complication in 1 patient. The idiopathic onset in 5 patients with PVT and 8 patients with SMVT was suspect to be due to congenital thrombophilia. Some patients had more than 2 causes of thrombosis. None of the patient has in this study had an abnormal hematological phenotype.

###### 

Patients With Superior Mesenteric Venous Thrombosis.

![](10.1177_1076029618774146-table1)

  Case   Sex   Age (years)   Onset (years)   Thrombotic Complications   AT (%)   PC (%)   PS (%)   Cause   Outcome   Anticoagulant             
  ------ ----- ------------- --------------- -------------------------- -------- -------- -------- ------- --------- --------------- --------- ---------------
  1      M     62            2012, 2013      PVT                        86.2     51^a^    37^a^    118     ND        Infection       Survive   Warfarin
  2      M     63            2007, 2013      CVST, PVT                  88.4     54^a^    48^a^    27^a^   69^a^     Idiopathic      Survive   Warfarin
  3      F     52            2011            PVT                        82.7     84       111      46      81.2      Idiopathic      Survive   Warfarin
  4      M     41            2012            PVT                        50.1     102      106      120     140       Idiopathic      Survive   Warfarin
  5      M     40            2010, 2014      PVT, CVST                  99.1     90       93       44^a^   46^a^     APS             Survive   Warfarin
  6      M     38            2016            PVT                        63.4     94       74       107     143       Idiopathic      Survive   UFH, warfarin
  7      M     40            2009            DVT                        79.8     24       18       101     110       Idiopathic      Survive   Warfarin
  8      M     77            2015                                       86.4     89       83       85      ND        BDC             Survive   Anti-Xa
  9      M     47            2011                                       37.0     96       103      ND      97        Idiopathic      Survive   Warfarin
  10     F     71            2007, 2009      CVST                       114      49^a^    50^a^    10^a^   40.5^a^   Idiopathic      Survive   Warfarin
  11     M     81            2015                                       88.1     68.0                                BDC, ope        Survive   UFH, warfarin
  12     F     31            1992, 1995      CT, CVST                   98.1     \<1.0    \<1.0    ND      ND        Idiopathic      Survive   Warfarin

Abbreviations: AC, activity; AG, antigen; APS, antiphospholipid syndrome; AT, antithrombin; BDC, biliary duct cancer; CT, cerebral thrombosis; CVST, cerebral venous sinus thrombosis; DVT, deep vein thrombosis; F, female; M, male; ope, operation; PC, protein C; PS, protein S; PVT, portal vein thrombosis; UFH, unfractionated heparin.

^a^The patient was treated with warfarin.

###### 

Patients With Portal Vein Thrombosis.^a^

![](10.1177_1076029618774146-table2)

  Case   Sex   Age (years)   Onset        Complications   AT (%)   PC (%)   PS (%)   Causes   Outcome   Anticoagulant                            
  ------ ----- ------------- ------------ --------------- -------- -------- -------- -------- --------- ------------------------------ --------- ----------------
  1      M     62            2012, 2013   SMVT            86.2     51^b^    37^b^    118      ND        Infection                      Survive   UFH, warfarin
  2      M     63            2007, 2013   CVST, SMVT      88.4     54^b^    48^b^    27^b^    69^b^     Idiopathic                     Survive   Warfarin
  3      F     52            2011         SMVT            82.7     84       111      46       81.2      Idiopathic                     Survive   Warfarin
  4      M     41            2012         SMVT            50.1     102      106      120      140       Idiopathic                     Survive   Warfarin
  5      M     40            2010, 2014   SMVT, CVST      99.1     90       93       44^b^    46^b^     APS                            Survive   Warfarin
  6      M     38            2016         SMVT            63.4     94       74       107      143       Idiopathic                     Survive   UFH, warfarin
  13     M     81            2015                         88.1     68.0                                 BDC, ope                       Survive   UFH, warfarin
  14     M     54            2013         DIC, TMA        30.8                                          LDLT                           Death     AT, FFP
  15     M     63            2012         DVT, PE         98.1     83       74       62                 CC                             Survive   UFH, warfarin
  16     F     60            2016         CB              61+      \+       \+       \+       \+        BDC, ope                       Death     UFH
  17     F     27            2014         DVT, PE         89.9     61       43       88       106       UC, ope                        Survive   UFH, warfarin
  18     F     63            2013                         33       24                37                 LF                             Survive   UFH, warfarin
  19     M     64            2012                         88.9     132      118      97                 Pancreatic cancer, ope, EPLT   Survive   UFH, warfarin
  20     F     59            2015                         59.2     53                61                 Pancreatic cancer, ope         survive   UFH, warfarin
  21     M     58            2014                         110               74                144       Ope                            Survive   UFH
  22     F     55            2013         DIC             96.2     78       67       72       72        DIC                            Survive   UFH
  23     M     37            2012         CVST            119      92.9              12       53        None                           Survive   UFH, warfarin
  24     M     77            2012         ITP, SAH, DIC   41.2                                          Ope, BDC                       Survive   UFH, warfarin
  25     M     77            2013         CT              72.1     62       46.5     68       64.9      SC                             Survive   UHF, warfarin
  26     F     65            2014                         32.5     62                60                 Pancreatic cancer, ope         Survive   UFH, warfarin
  27     F     70            2016                         55.3                                          HCC                            Survive   UFH, warfarin
  28     F     58            2013         MB              89       54       42       45       47        Ope                            Survive   LMWH, warfarin
  29     M     77            2015         DIC             47.0     21                50                 UTC                            Survive   UFH, AT
  30     F     74            2015         LF                                                            LF                             Survive   UFH, warfarin
  31     M     74            2012         DVT             89       78                13       21        Pancreatitis                   Survive   UFH, warfarin
  32     M     61            2012                                  42       27       62                 LDLT                           Survive   UFH, warfarin
  33     F     55            2013                         53.7                                          Pancreatic cancer, ope         Survive   UFH, warfarin

Abbreviations: AC, activity; AG, antigen; APS, antiphospholipid syndrome; AT, antithrombin; BDC, biliary duct cancer; CB, cerebral bleeding; CC, colon cancer; CT, cerebral thrombosis; CVST, cerebral venous sinus thrombosis; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; EPL, elevated platelet count; F, female; FFP, fresh frozen plasma; HCC, hepatic cell carcinoma; ITP, idiopathic thrombocytopenic purpura; LDLT, living donor liver transplantation; LF, liver failure; LMWH, low-molecular-weight heparin; M, male; MB, massive bleeding; Ope, operation; PC, protein C; PE, pulmonary embolism; PS, protein S; SAH, subarachnoid hemorrhage; SC, stomach cancer; SMVT, superior mesenteric venous thrombosis; TMA, thrombotic microangiopathy; UC, ulcerative colitis; UTC, urinary tract cancer.

^a^(+) denotes no abnormality by gene analysis.

^b^The patient was treated with warfarin.

The AT deficiency was observed in 3 of 12 patients with SMVT and 11 of 27 patients with PVT. The PC deficiency was observed in 6 of 12 patients with SMVT and 11 of 27 patients with PVT; PS deficiency was observed in 4 of 12 patients with SMVT and 13 of 27 patients with PVT. When AT, PC, and PS were measured, 5 patients with SMVT and 3 patients with PVT were already being treated with warfarin. Ultimately, all 12 patients with SMVT and the 27 patients with PVT survived and were treated with unfractionated heparin, warfarin, and anti-Xa agent. The AT, PC, or PS level was low in 1 patient with DIC and 1 patient with liver failure.

In the gene analysis ([Table 3](#table3-1076029618774146){ref-type="table"}), mutations in AT, PC, or PS were detected in 9 of 32 patients; 7 patients had SMVT, 5 had PVT, and 3 had both PVT and SMVT. Eight patients with a gene mutation for AT, PC, or PS had multiple thromboses, including DVT, PE, CVST, PVT, or SMVT, but 1 patient had only MVT. Of 9, 8 patients with a gene mutation for AT, PC, or PS had an idiopathic onset for SMVT or PVT, and they had no malignancy. There were 4 mutations in the PS gene, 3 in the PC gene, and 2 in the AT gene. The PS Tokushima was detected in 3 of 4 patients with a PS gene mutation and was associated with 2 other PS gene mutations. Case 12 was combined heterozygous for PC and had multiple and recurrent thromboses. The age was significantly lower in patients with a gene mutation for AT, PC, or PS than in those without such mutations, and the rates of multiple thromboses (*P* \< .001), idiopathic onset (*P* \< .001), and nonmalignancy (*P* \< .01) were significantly higher in those with mutations than in those without mutations ([Table 4](#table4-1076029618774146){ref-type="table"}).

###### 

Gene Mutation for AT, PC, and PS.

![](10.1177_1076029618774146-table3)

  Case   Sex   Age (years)   Complication      Cause        Deficiency   Gene Mutation
  ------ ----- ------------- ----------------- ------------ ------------ --------------------------------------------------------------
  2      M     63            SMVT, CVST, PVT   Idiopathic   PS           c.586A\>G (PS Tokushima), p.Lys196Glu
  3      F     52            SMVT, PVT         Idiopathic   PS           c.416C\>T, p.Ala139Val
  4      M     41            SMVT, PVT         Idiopathic   AT           c.208C\>T, p.Gln70X
  7      M     40            SMVT, DVT         Idiopathic   PC           c\. 1218 G\>A, p. Met408Ile
  9      M     47            SMVT              Idiopathic   AT           c.318delT, p.Asp106Glu fsX8
  10     F     71            SMVT, CVST        Idiopathic   PS           c.566G\>C p.Gly189Ala, c.586A\>G p.Lys196Glu, (PS Tokushima)
  12     F     31            SMVT, CT, CVST    Idiopathic   PC           c.202G\>A, p.Glu68Lys c.1208delG, p.Gly423ValfsX82
  17     F     27            PVT, DVT, PE      UC, ope      PC           c.400G\>T, p.Glu134X
  23     M     37            PVT, CVST         Idiopathic   PS           c.586A\>G (PS Tokushima), p.Lys196Glu

Abbreviations: AT, antithrombin; CT, cerebral thrombosis; CVST, cerebral venous sinus thrombosis; DVT, deep vein thrombosis; F, female; M, male; ope, operation; PC, protein C; PE, pulmonary embolism; PS, protein S; PVT, portal vein thrombosis; SMVT, superior mesenteric venous thrombosis; UC, ulcerative colitis.

###### 

Differences Between Patients With and Without Gene Mutations.^a^

![](10.1177_1076029618774146-table4)

                        With Gene Mutation   Without Gene Mutation   Difference (*P* Value)
  --------------------- -------------------- ----------------------- ------------------------
  Age                   41.0 (35.5-54.8)     63.0 (58.0-75.5)        .01
  Sex (F:M)             4:5                  9:15                    NS
  Relapse               3/9                  2/24                    NS
  Multiple thrombosis   8/9                  4/24                    .001
  Survive               9/9                  24/24                   NS
  Causes of onset                                                    
   Idiopathic           8/9                  1/24                    .001
   Postoperative        1/9                  12/24                   NS
   Malignancy           0/9                  13/24                   .01

Abbreviations: M. male; F, female; NS, nonsignificant.

^a^Some patients had more than 2 causes of thrombosis.

Discussion {#section7-1076029618774146}
==========

Our study showed that SMVT was frequently caused by an AT, a PC, or a PS mutation, and the onset of SMVT due to thrombophilia was frequently idiopathic. Both SMVT and PVT, especially SMVT, were frequently associated with other thromboses, such as CVST, PVT, SMVT, DVT, and PVT. Furthermore, the frequency of complication with relatively rare thromboses, aside from DVT/PE, was high. Given the small population in our study, there were no significant differences in the age and sex between patients with SMVT and PVT, although patients with SMVT tended to be younger than those with PVT or DVT after surgery.^[@bibr15-1076029618774146]^ All cases in this study survived, in agreement with previous report.^[@bibr16-1076029618774146]^

We previously reported the frequency of congenital thrombophilia to be 31.8% in patients with CVST^[@bibr12-1076029618774146]^ and 30.0% in patients with DVT or PE, including 11.5% with AT mutations, 12.3% with PC mutations, and 6.2% with PS mutations.^[@bibr14-1076029618774146]^ At the onset of thrombosis, decreased levels of AT, PC, or PS were observed in patients without congenital thrombophilia.^[@bibr14-1076029618774146],[@bibr17-1076029618774146]^ Few reports have described thrombophilia in PVT and SMVT.^[@bibr18-1076029618774146][@bibr19-1076029618774146]--[@bibr20-1076029618774146]^

Patients with SMVT or PVT were frequently associated with a deficiency in PC or PS; however, these patients were often treated with warfarin, indicating that a gene analysis is useful for diagnosing congenital thrombophilia in such patients.

A gene analysis detected mutations in AT, PC, or PS in about 27% of patients with PVT or SMVT. Case 12 was previously reported as having a combined heterozygous PC deficiency^[@bibr21-1076029618774146]^ and cases 2, 10, and 23 were previously reported as having CVST.^[@bibr22-1076029618774146]^ In our study, the rate of PS mutation tended to be higher in PVT or MVT than in DVT/PE.^[@bibr14-1076029618774146]^ Although our sample size was small, this tendency is similar to that noted with CVST.^[@bibr12-1076029618774146]^ The PS Tokushima mutation was detected in 3 of 4 patients with a PS mutation, which is frequently observed in Japanese people.^[@bibr23-1076029618774146],[@bibr24-1076029618774146]^ Although the frequency of multiple thromboses was significant in cases of congenital thrombophilia with PVT or SMVT, there was no significant difference in the rate of relapse between PVT/SMVT with and without congenital thrombophilia, possibly due to our small sample size. The age was significantly younger, and the rate of idiopathic onset and nonmalignancy was significantly higher in patients with congenital thrombophilia than in those without. These findings were similar to those in previous reports on DVT/PE.^[@bibr14-1076029618774146]^ The Janus activating kinase 2 (JAK2) p.V617V mutation is a well-known risk factor for thrombosis in patients with myeloproliferative neoplasm.^[@bibr25-1076029618774146]^ However, since no abnormal hematological phenotypes were observed in this study, this mutation was not analyzed.

In conclusion, PVT and SMVT are frequently associated with congenital thrombophilia, such as AT, PC, or PS mutations. Young patients with an idiopathic onset of PVT or MVT with multiple thromboses should be considered at risk of having congenital thrombophilia.
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